» Articles » PMID: 30093263

Negative Lymph Node Count and Lymph Node Ratio Are Associated With Survival in Male Breast Cancer

Overview
Publisher Elsevier
Specialty Oncology
Date 2018 Aug 11
PMID 30093263
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Male breast cancer (MBC) is usually diagnosed at late stages and therefore has a worse prognosis than female breast cancer (FBC). MBC is also more likely to have lymph node (LN) involvement than FBC.

Materials And Methods: We sought to determine the prognostic role of the examined lymph node (LN), negative LN (NLN), and positive LN counts and the LN ratio (LNR), defined as (positive LNs/ENLs), on the survival rate among MBC patients. We performed a large population-based study using the data from the Surveillance, Epidemiology, and End Results program.

Results: Older age, black race, stage IV disease, ≤ 1 NLN, and a > 31.3% LNR were significantly associated with worse survival across all prediction models. Moreover, we demonstrated a decreased risk of mortality in MBC patients across the MBC-specific survival model (hazard ratio, 0.98; 95% confidence interval, 0.96-0.998; P = .03) and 10-year MBC-specific survival model (hazard ratio, 0.98; 95% confidence interval, 0.96-0.999; P = .04).

Conclusion: MBC has had an augmented incidence over the years. We found several independent predictors of MBC survival, including age, race, stage, NLNs, and the LNR. We strongly suggest adding the NLN count and/or LNR into the current staging system. Further studies are needed to provide information on the mechanisms underlying the association between the NLN count and MBC survival and the LNR and MBC survival.

Citing Articles

Comparative evaluation of negative lymph node count, positive lymph node count, and lymph node ratio in prognostication of survival following completely resection for non-small cell lung cancer: a multicenter population-based analysis.

Huang Q, Chen S, Xiao Y, Chen W, He S, Xie B Front Surg. 2024; 11:1506850.

PMID: 39717353 PMC: 11663925. DOI: 10.3389/fsurg.2024.1506850.


A 3 M Evaluation Protocol for Examining Lymph Nodes in Cancer Patients: Multi-Modal, Multi-Omics, Multi-Stage Approach.

Wang R, Zhang Z, Zhao M, Zhu G Technol Cancer Res Treat. 2024; 23:15330338241277389.

PMID: 39267420 PMC: 11456957. DOI: 10.1177/15330338241277389.


Nomograms to predict the long-term prognosis for non-metastatic invasive lobular breast carcinoma: a population-based study.

Guan Y, Huang S, Yu B Sci Rep. 2024; 14(1):19477.

PMID: 39174612 PMC: 11341842. DOI: 10.1038/s41598-024-68931-5.


Postoperative survival effect of the number of examined lymph nodes on esophageal squamous cell carcinoma with pathological stage T1-3N0M0.

Wu L, Zhong J, Zhu J, Kang L, Huang Y, Lin P BMC Cancer. 2022; 22(1):118.

PMID: 35090428 PMC: 8800278. DOI: 10.1186/s12885-022-09207-x.


The prognostic value of lymph node ratio in comparison to positive lymph node count in penile squamous cell carcinoma.

Yu J, Long Q, Zhang Z, Liao S, Zheng F Int Urol Nephrol. 2021; 53(12):2527-2540.

PMID: 34585313 PMC: 8599252. DOI: 10.1007/s11255-021-02996-3.